Tamoxifen better than Lilly's Evista at preventing breast cancer
This article was originally published in Scrip
Executive Summary
The generic selective estrogen-receptor modulator (SERM), tamoxifen, is more effective at preventing breast cancer than Lilly's Evista (raloxifene), another drug in the same class, according to updated results of the STAR trial, which were presented this week at the American Association for Cancer Research (AACR) conference in Washington, DC.